Lv5
970 积分 2021-07-23 加入
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
3天前
已完结
The next big questions in cancer research
30天前
已完结
Diagnostic and Prognostic Ability of Contrast-Enhanced Unltrasound and Biomarkers in Hepatocellular Carcinoma Subtypes
1个月前
已完结
Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development
2个月前
已完结
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma
2个月前
已完结
Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study
2个月前
已完结
Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply
3个月前
已完结
Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
3个月前
已完结
Clinical application of circulating tumour DNA in colorectal cancer
3个月前
已完结
Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer
3个月前
已完结
皖公网安备34019202002308
